1-methyl-3-(4-nitrophenyl)urea | 13866-64-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-3-(4-nitrophenyl)urea
• 英文别名: N-Methyl-N'-<4-nitro-phenyl>-harnstoff；N-methyl-N'-(4-nitro-phenyl)-urea；N-Methyl-N'-(4-nitro-phenyl)-harnstoff；N-Methyl-N'-(4-nitrophenyl)urea
• CAS: 13866-64-3
• 化学式: C₈H₉N₃O₃
• mdl: MFCD09040539
• 分子量: 195.178
• InChiKey: KLRUCOUQQILQEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  87
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-3-(4-nitrophenyl)urea 、 四丁基醋酸铵 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  不对称尿素、硫脲和方酰胺受体作为最小阴离子结合基序

  摘要：

  基于 4-硝基苯基脲 1 和 4-硝基苯基硫脲 2 的不对称最小受体被证明可以结合一系列阴离子，并被氟化物和氢氧化物去质子化，产生颜色......

  DOI：

  10.1080/10610278.2024.2307016
• 作为产物：
  描述：

  硝酸乙酯 、 1-甲基-1-苯基脲 在 硫酸 作用下， 生成 1-methyl-3-(4-nitrophenyl)urea
  参考文献：
  名称：

  Scholl; Holdermann, Justus Liebigs Annalen der Chemie, 1906, vol. 345, p. 377

  摘要：

  DOI：

文献信息

• Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents
  申请人：Sattigeri Vishwajanani Jitendra

  公开号：US20090048186A1

  公开（公告）日：2009-02-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了含有本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。
• NOVEL HYDROGELATOR
  申请人：NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY

  公开号：US20190241598A1

  公开（公告）日：2019-08-08

  A novel hydrogelator that contains a monourea compound having a sugar structure, which can be produced by a simple method, includes a compound of the following Formula [1]: (wherein S g is a sugar group, A is a divalent linking group, and R is a linear or branched alkyl group having a carbon atom number of 1 to 15, a cyclic alkyl group having a carbon atom number of 3 to 15, a linear or branched alkenyl group having a carbon atom number of 2 to 15, or a C 6-18 aryl group unsubstituted or substituted with at least one substituent selected from the group consisting of a C 1-10 alkyl group, a C 1-10 alkoxy group, a C 6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C 2-10 alkylcarbonyl group, and a C 7-18 aralkyl group).

  一种新型水凝胶剂，包含具有糖结构的单脲化合物，可以通过简单的方法制备，包括以下式[1]的化合物：（其中S是糖基，A是二价连接基团，R是线性或支链烷基，碳原子数为1至15，环状烷基，碳原子数为3至15，线性或支链烯基，碳原子数为2至15，或未取代或取代至少一个取代基的C6-18芳基，所述取代基选择自C1-10烷基，C1-10烷氧基，C6-18芳氧基，卤素原子，硝基，苯基，C2-10烷基羰基和C7-18芳基烷基组成）。
• Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US10351522B2

  公开（公告）日：2019-07-16

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，该化合物具有奥曲肽受体激动剂活性，有望用作嗜睡症等的预防或治疗药物。本发明提供了一种由式（I）代表的化合物： 其中各符号如描述中所定义，或其药学上可接受的酸加成盐，具有奥曲肽受体激动剂活性，以及含有该化合物或其药学上可接受的酸加成盐的奥曲肽受体激动剂。
• Selective carbamoylation with methyl isocyanate
  作者：Walter R. Benson、Benjamin Kagan、Ernest Lustig、Jo-Yung Tung Chen、Joel Shulman

  DOI：10.1021/jo01286a074

  日期：1967.11